排除鳞状细胞肺癌的患者和那些治疗前有咯血的患者后，贝伐单抗治疗导致的致命率就会下降到1.9%。

By excluding patients with squamous-cell lung cancer and those with hemoptysis prior to treatment, the rate was brought down to 1.9%.

youdao

贝伐单抗，也是没有用的情况下鳞状细胞癌，因为它会导致出血，从这种类型的肺癌。

Bevacizumab is also not used in cases of squamous cell cancer, because it leads to bleeding from this type of lung cancer.

youdao

与从未吸烟者相比，目前和原来吸烟者患有较其他类型难于治疗的鳞状上皮细胞和小细胞肺癌的比例较高。

Compared to never smokers, current and former smokers had proportionally more squamous cell and small-cell lung cancer, which can be harder to treat than other subtypes.

youdao